Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Early Breast Cancer
Phase PHASE2
Enrollment 1163
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The investigator conduct a phase II multi-center, open-label trial to evaluate efficacy and safety of dalpiciclib with endocrine therapy as adjuvant treatment in patients with medium /high risk hormone receptor-positive, HER2-negative Early Breast Cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dalpiciclib — CDK4/6 inhibitor dalpiciclib, 100mg orally qd
  • Drug: Endocrine therapy — Fulvestrant/AI

Primary Outcomes

  • invasive Disease-free Survival (iDFS) (From enrollment until time of events up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-11-17
Completion: 2029-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1163 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Contact Information
Study Contact:
Xiaoan Liu, Professor
025-68308162
liuxiaoan@126.com
Xiaoan Liu, Professor
025-68308162
liuxiaoan@126.com
The First Affiliated Hospital of Nanjing Medical University
Interventions
  • Drug: Dalpiciclib — CDK4/6 inhibitor dalpiciclib, 100mg orally qd
  • Drug: Endocrine therapy — Fulvestrant/AI
Study Locations (1 sites)
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu China
Eligibility Criteria
Inclusion Criteria: * Patient is ≥ 18 years-old * Patient is female with known menopausal status (postmenopausal or premenopausal/perimenopause) * Patient with histologically confirmed HR+/HER2- early breast cancer (immunohistochemical ER and/or PR≥10%) * Histologically confirmed invasive breast cancer with anatomic stages of IIA-IIIC stage (T2-4N0-3M0), of which stage IIA only included T1N1M0 * Patients with or without neoadjuvant or adjuvant chemotherapy/ radiotherapy were eligible for inclusion * From operation to enrollment should not exceed 12 months * Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Exclusion Criteria: * metastatic disease (Stage IV) or inflammatory breast cancer * Previous or current history of malignant neoplasms, except for curatively treated:Basal and squamous cell carcinoma of the skin,Carcinoma in situ of the cervix. * Clinically relevant cardiovascular disease:Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension ≥180/110); * A history of allergy to the drugs in this study; * Unable or unwilling to swallow tablets * History of gastrointestinal disease with diarrhea as the major symptom.
Conditions HER2-Low Unresectable/Metastatic Breast ...
Phase PHASE2
Enrollment 184
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if Trastuzumab Rezetecan (SHR-A1811) is safe and tolerable for patients with HER2-Low unresectable/metastatic breast cancer complicated with visceral crisis. Participants will take Trastuzumab Rezetecan every three weeks, until disease progression or intolerable toxicity.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Trastuzumab Rezetecan — Trastuzumab Rezetecan 4.8mg/kg, IV, Day 1, Q3W
  • Drug: Chemotherapy of Physician's Choice — Chemotherapy of Physician's Choice, including nab-paclitaxel, Eribulin, Capecitabine, Vinorelbine, Gemcitabine.

Primary Outcomes

  • Progression-Free Survival (PFS) (From the start of treatment to 36 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-01
Completion: 2030-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 184 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Fei Ma M.D
01087788060
drmafei@126.com
Cancer Hospital, Chinese Academy of Medical Sciences
Interventions
  • Drug: Trastuzumab Rezetecan — Trastuzumab Rezetecan 4.8mg/kg, IV, Day 1, Q3W
  • Drug: Chemotherapy of Physician's Choice — Chemotherapy of Physician's Choice, including nab-paclitaxel, Eribulin, Capecitabine, Vinorelbine, Gemcitabine.
Study Locations (1 sites)
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: * Age: ≥18 years old and ≤75 years old; * Pathologically confirmed HER2-Low unresectable or metastatic breast cancer; * Visceral crisis is defined as severe organ dysfunction as assessed by signs, symptoms and laboratory studies, resulting from rapid progression of neoplastic disease and indicative of substantial visceral compromise that may serve as an indication for more aggressive therapeutic intervention, including:a)Liver visceral crisis: rapidly increasing bilirubin \>1.5 × ULN in the absence of Gilbert's syndrome or biliary tract obstruction;b)Lung visceral crisis: rapidly increasing dyspnoea at rest, not alleviated by drainage of pleural effusion;c)Other visceral crises: the evaluation is conducted by the clinician based on the definition of visceral crisis specified in the ABC7 guideline. * Patients whom investigators deem to have indications for single-agent chemotherapy. * Sufficient bone marrow function, defined as follows:a) Neutrophil count (ANC) ≥ 1,500/mm³ (1.5 × 10⁹/L);b) Platelet count (PLT) ≥ 80 ×10\^9/L;c) Hemoglobin (Hb) ≥ 80 g/L; * Patients who have received ≤ 1 line of chemotherapy in the advanced stage are permitted. * Patients who have received endocrine therapy in the advanced stage are permitted. * Previous treatment with CDK4/6 inhibitors is permitted. * Previous or concurrent local treatment for symptom relief is permitted. * For female subjects who are premenopausal or not surgically sterilized: A serum pregnancy test must be performed within 7 days before the first dose of study drug, with a negative result. They must agree to either abstain from sexual activity or use a medically approved highly effective contraceptive method from the time of signing the informed consent form, throughout the study period, and for 1 year after the last dose of study drug. * Patients must voluntarily participate in this study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up. Exclusion Criteria: * Have received treatment with new antibody-drug conjugates (ADCs) at any stage of breast cancer. * Are deemed by the investigator as unsuitable for systemic chemotherapy. * Have had other malignant tumors within the past 5 years, excluding cured carcinoma in situ of the cervix, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma (patients with other malignant tumors that occurred more than 5 years before randomization and were cured solely by surgery are eligible for enrollment). * Have undergone major surgical procedures or suffered significant trauma within 4 weeks prior to randomization, or are expected to undergo major surgical treatment. * Have severe heart disease or cardiac discomfort, including but not limited to the following conditions:a) A history of heart failure or systolic dysfunction (left ventricular ejection fraction \[LVEF\] \< 50%);b) High-risk angina pectoris requiring treatment or cardiac arrhythmias;c) Clinically significant valvular heart disease;d) ECG findings indicating transmural myocardial infarction;e) Poorly controlled hypertension. * Have a known history of allergy to any component of the drugs in this protocol. * Have a history of immunodeficiency, including HIV infection, or other acquired or congenital immunodeficiency diseases. * Have a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. * Have a known history of psychotropic substance abuse or drug addiction. * Are pregnant or lactating women, or women of childbearing age who are unwilling to use effective contraceptive measures throughout the trial period and within 7 months after the last administration of the study drug. * Have severe diseases, other comorbidities that would interfere with the planned treatment, or any other conditions that make them unsuitable for participation in this study (e.g., active hepatitis B, pulmonary infection requiring treatment).
Conditions Triple Negative Breast Cancer
Phase NA
Enrollment 450
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

CUPCAKE is a randomized, non-comparative, multicenter, proof-of-concept phase II trial, using the Trials within Cohorts concept(1) to assess the clinical utility of ctDNA monitoring combined with 68Ga-FAPI-46-PET-CT imaging upon ctDNA detection for the surveillance of patients with a non-metastatic TNBC at high risk of relapse. The study has two steps. In Step 1, patients who have completed the treatments for a localized TNBC will undergo ctDNA monitoring every \~4 months (± 2 weeks). In Step 2, patients for whom ctDNA will be detected will then be randomized between an observation arm, in which monitoring will continue until the detection of a clinical relapse, and an experimental arm, in which the ctDNA detection will be revealed to both the patient and the clinician: patients will then undergo a 18F-FDG PET-CT and a 68Ga-FAPI-46-PET-CT, in addition to whatever workup the investigator will deem necessary.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: Triple

Interventions / Regimen

  • Diagnostic Test: ctDNA monitoring — For each patient included, a ctDNA detection assay will be performed in blood samples every 4 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.
  • Diagnostic Test: 68Ga-FAPI-46-PET-CT — ). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.

Primary Outcomes

  • Overall survival (36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-05
Completion: 2031-08-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 450 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Curie
Collaborators: National Research Agency, France, Roche Pharma AG, Personalis Inc., UNICANCER
Principal Investigators:
  • François-Clément BIDARD (PRINCIPAL_INVESTIGATOR) - Institut Curie
Contact Information
Study Contact:
Anne-Claire COYNE
0147111515
drci.promotion@curie.fr
Julien GRENIER
Sainte-Catherine Institut du Cancer Avignon-Provence
Julien GRENIER
Sainte-Catherine Institut du Cancer Avignon-Provence
Interventions
  • Diagnostic Test: ctDNA monitoring — For each patient included, a ctDNA detection assay will be performed in blood samples every 4 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.
  • Diagnostic Test: 68Ga-FAPI-46-PET-CT — ). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.
Study Locations (13 sites)
Sainte-Catherine Institut du Cancer Avignon-Provence, Avignon, 84918 France
Institut Bergonié, Bordeaux, 33000 France
Centre Jean Perrin, Clermont-Ferrand, 63011 France
Centre Leon Bérard, Lyon, 69008 France
Institut Paoli-Calmettes, Marseille, 13009 France
Institut du cancer de Montpellier, Montpellier, 34298 France
CHU Nîmes, Nîmes, 30900 France
Hôpital Saint-Louis, Paris, 75010 France
Hôpital Tenon, Paris, 75020 France
Centre Eugène Marquis, Rennes, 35000 France
Eligibility Criteria
Inclusion Criteria: 1. Patients must have signed a written informed consent before inclusion 2. Patients must be female ≥ 18 years old 3. Patients diagnosed with a non-metastatic TNBC (ER \& PR \<10%, HER2- per ASCO/CAP guidelines). Patients must have been previously evaluated by a 18F-FDG PET-CT or a bone scintigraphy combined with a thorax, abdomen and pelvis CT scan with contrast 4. Patients who have undergone surgery with curative intent for their non-metastatic TNBC. Surgery must have been performed between 3 to 24 months before inclusion. Patients must have initiated their adjuvant therapy, whenever indicated, since at least 12 weeks. For patients receiving an experimental adjuvant treatment in a clinical trial, any intervention planned as part of this trial must be completed before inclusion. 5. High-risk primary tumor, defined as: 1. Lack of pathological complete response after neoadjuvant chemotherapy (RCB I, II or III; RCB I being capped to a maximum of 30% of included patients) OR, in the absence of neoadjuvant chemotherapy, 2. Stage IIB-III (i.e., T2N1, any T3-T4, any N2-3) OR 3. Any loco-regional relapse occurring after a prior ipsilateral, curatively treated TNBC 6. No sign of local or distant relapse, as per investigator assessment 7. Performance status \< 2 8. Available FFPE tumor block with \> 10% cellularity or 11 tumor sections with \>10% cellularity 9. Patient able to comply with protocol requirements 10. Patients covered by a health insurance Exclusion Criteria: 1. Any uncontrolled disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding or any other medical condition that, in the opinion of the investigator, interferes with the trial procedures 2. Male participants 3. Patients with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent. 4. Patients who have difficulty undergoing trial procedures for geographic, social or psychological reasons 5. Person deprived of liberty or under guardianship 6. History of another primary malignancy except for the following : 1. Basal cell carcinoma or any in situ carcinoma treated with curative intent 2. Any stage I-II malignancy treated with curative intent with no evidence of active disease in the last five years 7. For step #2 (randomization after ctDNA detection): clinical/radiological metastatic relapse before the detection of the molecular relapse.
Conditions Breast Neoplasms, Mastectomy, Nerve Bloc...
Phase NA
Enrollment 1206
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

Chronic postsurgical pain (CPSP) has an incidence of 46% in patients after breast cancer surgery, which seriously affects patients' physiological and psychological function, as well as quality of life. Acute pain is an independent risk factor for persistent pain after surgery. Erector spinae plane block (ESPB) provided excellent perioperative analgesia in patients undergoing breast surgery. Dexmedetomidine as an adjuvant of local anesthetics prolongs the duration of peripheral nerve block and decreases the requirements of postoperative analgesia. The investigators hypothesize that, for breast cancer patients undergoing mastectomy, ESPB (with a combination of 0.5% ropivacaine 35 ml and dexmedetomidine 1 microgram/kg) can reduce the occurrence of CPSP. The purpose of this randomized controlled trial is to investigate the impact of ESPB with adjuvant dexmedetomidine on the incidence of CPSP in breast cancer patients after mastectomy. We will also observe the impact of ESPB on long-term survival in these patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Procedure: Erector spinae plane block — Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1 microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
  • Procedure: Control group — General anesthesia alone.

Primary Outcomes

  • Incidence of chronic postsurgical pain (CPSP) at 6 months after surgery (At 6 months after surgery)
  • Progression-free survival (long-term outcomes) (Up to 3 years after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-23
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1206 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University First Hospital
Collaborators: Peking University Cancer Hospital & Institute
Principal Investigators:
  • Dong-Xin Wang, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR) - Peking University First Hospital
Contact Information
Study Contact:
Qiongfang Wu, M.D.
+8618310161109
wuqf91@163.com
Dong-Xin Wang, M.D., Ph.D.
+86 13910731903
wangdongxin@hotmail.com
Zeng-Mao Lin, M.D.
+86 13810098351
Linzengmao@163.com
Peking University First Hospital
Interventions
  • Procedure: Erector spinae plane block — Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1 microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
  • Procedure: Control group — General anesthesia alone.
Study Locations (2 sites)
Peking University First Hospital, Beijing, Beijing Municipality 100034 China
Beijing Cancer Hospital, Beijing, Beijing Municipality 100142 China
Eligibility Criteria
Inclusion Criteria: 1. Age of 18 years or over, but less than 85 years; 2. Scheduled to undergo mastectomy for primary unilateral breast cancer. Exclusion Criteria: 1. Previous breast cancer surgery with an incision of \>2 cm; 2. Chronic opioid dependence or long-term intake of analgesic medicines (\>3 months); 3. Any contraindication to erector spinae plane block, including intrathoracic infection, infection at the puncture site, cancer invasion of the puncture site, severe spinal deformity, history of spinal surgery, and severe coagulopathy; 4. Inability to communicate in the preoperative period because of profound dementia, deafness, language barriers, or end-stage disease; 5. History of malignant tumor in other organs, or a current combination of malignant tumor of other organs; 6. History of coronary heart disease (diagnosed coronary stenosis, previous myocardial infarction, previous percutaneous coronary intervention or coronary artery bypass grafting); preoperative hepatic or renal impairment (alanine transaminase and/or aspartate transaminase ≥2 times of upper limit of normal, or serum creatinine\>133 µmol/L); history of peptic ulcer or hemorrhage; ASA classification IV or above; 7. Allergy to ropivacaine.
Conditions Breast Neoplasms, Lymphedema Due to Radi...
Phase Not Applicable
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn how the lymphatic system changes before and after radiotherapy in female patients with breast cancer. The study aims to understand early lymphatic changes that may lead to breast-cancer-related lymphedema (BCRL) and to help identify patients who might benefit from early preventive rehabilitation. The main questions it aims to answer are: How does lymphatic flow and vessel function change after radiotherapy, as measured by indocyanine green (ICG) lymphography? Can early imaging changes on ICG lymphography predict later swelling or lymphedema symptoms in the arm? There is no comparison or treatment group, since all participants will receive radiotherapy as part of their standard breast cancer care. Participants will: Undergo ICG lymphography before radiotherapy and again within 4-6 weeks after completing radiotherapy Receive a small injection of ICG dye under the skin and have near-infrared imaging to visualize lymphatic flow Complete follow-up assessments (for some participants) at 3, 6, or 12 months to monitor long-term lymphatic changes Continue their usual standard medical and rehabilitation care throughout the study This study will include 40 female participants, aged 18 years or older, who have been diagnosed with stage I-III breast cancer and are scheduled for postoperative radiotherapy. Participants with a history of lymphedema, prior radiotherapy, severe organ disease, or known ICG/iodine allergy will not be included. The information collected will include imaging findings from ICG lymphography, arm circumference and volume measurements, and patient-reported outcomes on arm discomfort or swelling. These data will help researchers identify early imaging biomarkers of radiation-induced lymphatic dysfunction. The study does not involve any experimental treatment or random assignment. All procedures are routine diagnostic or rehabilitation methods that are already approved for clinical use. The ICG test uses a very small amount of dye and is considered safe, with allergic reactions being rare. The findings of this study may provide new insights into how radiotherapy affects the lymphatic system and may contribute to developing personalized strategies to prevent or minimize lymphedema after breast cancer treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change in Lymphatic Function Before and After Radiotherapy Measured by ICG Lymphography (Baseline (before radiotherapy), 4-6 weeks after completion of radiotherapy, and optionally at 3, 6, and 12 months after RT completion if follow-up imaging is performed.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-05
Completion: 2028-10-18
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Inah Kim
Contact Information
Study Contact:
Inah Kim, M.D.,Ph.D
82-10-2937-6852
inahsylvia@gmail.com
Yongkyun Jung, M.D.
82-10-3681-7243
andnfn@naver.com
Inah Kim, M.D.,Ph.D
82-10-2937-6852
inahsylvia@gmail.com
Dongtan Sacred Heart Hospital
Interventions
N/A
Study Locations (1 sites)
Dongtan Sacred Heart Hospital, Hwaseong-si, Gyeonggido 18450 South Korea
Eligibility Criteria
Inclusion Criteria: * Female, ≥18 years old * Pathologically confirmed stage I-III breast cancer * Scheduled to receive postoperative radiotherapy (RT) Exclusion Criteria: * Previous or current lymphedema * Prior radiotherapy to the ipsilateral breast or axilla * Severe systemic diseases (heart, renal, hepatic failure) * Active infection * Pregnancy or lactation * Allergy to indocyanine green (ICG) or iodine-based contrast agents
Conditions Breast Carcinoma, Breast Neoplasm
Phase Not Applicable
Enrollment 550
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the effectiveness of a breast ultrasound method for the diagnosis of breast cancer. Diagnostic procedures, such as breast ultrasound, may help find and diagnose breast cancer, and may help measure a patient's response to earlier treatment. The purpose of this research is to test the effectiveness of a new investigational breast ultrasound method to detect an abnormality in the breast, and assess response to breast cancer treatment.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Procedure: Ultrasound — Undergo breast ultrasound

Primary Outcomes

  • Specificity of ultrasound in detection of breast cancer (Up to study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-09-01
Completion: 2027-11-29
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 550 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Azra Alizad, M.D. (PRINCIPAL_INVESTIGATOR) - Mayo Clinic in Rochester
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic in Rochester
Azra Alizad, M.D.
Mayo Clinic in Rochester
Interventions
  • Procedure: Ultrasound — Undergo breast ultrasound
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * AIM 1: Patient volunteers, ages \>= 18 with suspicious breast masses scheduled for breast biopsy, or at least two weeks or more after breast biopsy * AIM 2: Patient volunteers, ages \>= 18 who have biopsy proven breast cancer and are going under neoadjuvant chemotherapy and/or endocrine therapy had their baseline MRI and/or ultrasound Exclusion Criteria: * Patients with breast implants or any condition that does not allow proper use of ultrasound (US)
Conditions Breast Cancer, Breast Neoplasms, Breast ...
Phase NA
Enrollment 1600
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective clinical trial that will examine if biennial contrast-enhanced mammography added to annual 3D mammography (tomosynthesis) substantially improves breast cancer detection with minimal increase in false-positives, in women with a personal history of breast cancer.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Device: contrast-enhanced mammography — Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.

Primary Outcomes

  • Incremental Cancer Detection Rate (at 24 months, 48 months, and 62 months)
  • False-positive recall rate (at 24 months, 48 months, and 62 months)
  • Positive-predictive values (at 24 months, 48 months, and 62 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-08
Completion: 2031-04
Eligibility
Age: 30 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 1600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wendie Berg
Collaborators: Breast Cancer Research Foundation
Principal Investigators:
  • Wendie Berg, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Wendie Berg, MD, PhD
412-641-8278
bergwa@upmc.edu
McKenna Rigling, MS
412-641-8278
riglingmm@upmc.edu
McKenna Rigling, MS
412-641-8278
riglingmm@upmc.edu
UPMC Magee-Womens Imaging - Bethel Park
Interventions
  • Device: contrast-enhanced mammography — Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
Study Locations (6 sites)
UPMC Magee-Womens Imaging - Bethel Park, Bethel Park, Pennsylvania 15102 United States
UPMC Magee at the Lemieux Sports Complex, Cranberry Township, Pennsylvania 16066 United States
Magee Womancare Monroeville, Monroeville, Pennsylvania 15146 United States
Magee-Womens Hospital, Pittsburgh, Pennsylvania 15213 United States
Hillman Cancer Center at Shadyside, Pittsburgh, Pennsylvania 15232 United States
UPMC West Mifflin Outpatient Center, West Mifflin, Pennsylvania 15236 United States
Eligibility Criteria
Inclusion Criteria: * Asymptomatic women, ages 30-79, with a personal history of breast cancer who are at least one year out from any breast cancer surgery and/or treatment and are scheduled to have a routine annual mammogram with tomosynthesis (DBT). Exclusion Criteria: * Women with a history of prior moderate or severe iodinated contrast reaction \[only those with a prior mild reaction that can be managed by pre-medication AND with and a strong desire to participate will be allowed to participate. However, among these women with a mild sensitivity, if they are allergic to Benadryl (one of the premedications), they will be excluded\]. * Women with implant(s) in the breasts to be screened (as this creates artifacts and diagnostic performance of imaging in women with implants likely does not generalize to those without implants, and the sample size with implants would be too small to infer conclusions. * Women who have had bilateral mastectomy * Women with a history of kidney failure or estimated glomerular filtration rate (eGFR) \< 30 mL/min * Pregnancy or lactation * Women actively being treated for cancer of any type with chemotherapy. * Women with stage 4 metastasis to visceral areas or brain * Women with known personal history of breast cancer who have a screening breast MRI exam within 24 months prior to the current round of CEM. * Women with known personal history of breast cancer who had a CEM exam within the prior 23 months
Conditions Breast Neoplasm, Chemotherapy Effect
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The use of neoadjuvant chemotherapy in breast cancer is expanding in the recent decade. Patients with good response to neoadjuvant chemotherapy could benefit from de-escalation of breast and axilla operation. However, breast tumor and involved axillary lymph node should be marked before the commencement of chemotherapy. This could facilitate subsequent operative planning and intraoperative assessment of disease response. This study aims to evaluate the feasibility of magnetic marker localization for non-palpable breast cancer and targeted axillary dissection in patients with node-positive breast cancer following neoadjuvant therapy

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Magnetic seed localization — Magnetic seed guided localization

Primary Outcomes

  • Successful localization of breast tumor and axillary lymph node (At the time of operation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-10-15
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Collaborators: Endomagnetics Ltd.
Contact Information
Study Contact:
Chi Mei Vivian Man, FCSHK, FRCSEd
852-25898116
vivian27@hku.hk
Christine Chan, Miss
852-2255 4773
tcc0525@hku.hk
Christine Chan
852-22554765
tcc0525@hku.hk
University of Hong Kong
Interventions
  • Device: Magnetic seed localization — Magnetic seed guided localization
Study Locations (1 sites)
University of Hong Kong, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * All patients with cT1-3N1 invasive ductal carcinoma planned for neoadjuvant chemotherapy and/or target therapy * mentally competent to give informed consent * Agreed to proceed with curative operation after chemotherapy and tentatively keen for breast conservative surgery and targeted axillary dissection after neoadjuvant chemotherapy * Radiologically 1-3 ipsilateral axillary lymph node metastases confirmed by cytology or biopsy Exclusion Criteria: * Presence of distant metastasis, inflammatory breast cancers, multi-centric breast cancers * History of previous ipsilateral axillary surgery or irradiation * Hypersensitivity to dextran compounds or iron * Iron overload disease * Pregnant or lactating patients * Patients with pacemaker or other implantable metallic devices in chest wall or prosthesis in shoulder * Mentally incompetent patients
Conditions Breast Cancer
Phase PHASE3
Enrollment 766
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, randomized, open-label phase III clinical study on the efficacy and safety of fluzoparib combined with adjuvant endocrine therapy versus adjuvant endocrine therapy for HR+/HER2- SNF3-subtype early breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Fluzoparib — Fluzoparib 50mg bid orally for 1 year.
  • Drug: Anastrozole — 1mg, qd orally
  • Drug: Letrozole — 2.5mg, qd orally
  • Drug: Exemestane — 25mg, qd orally
  • Drug: Tamoxifen — 10mg, bid orally
  • Drug: Toremifene — 60mg, qd orally
  • Drug: Abemaciclib — 150mg/100mg/50mg, bid orally for 2 years
  • Drug: LHRH agonist — Leuprorelin acetate, goserelin acetate

Primary Outcomes

  • invasive disease free survival (iDFS) (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-06-01
Completion: 2031-05-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 766 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Zhimin Shao, MD, PhD
+86-021-64175590
zhimingshao@yahoo.com
HuiPing Li, MD
+86-010-88121122
Beijing Cancer Hospital
Xiaohua Zeng, MD
+86-023-65311341
Chongqing Cancer Hospital
Interventions
  • Drug: Fluzoparib — Fluzoparib 50mg bid orally for 1 year.
  • Drug: Anastrozole — 1mg, qd orally
  • Drug: Letrozole — 2.5mg, qd orally
  • Drug: Exemestane — 25mg, qd orally
  • Drug: Tamoxifen — 10mg, bid orally
Study Locations (15 sites)
Beijing Cancer Hospital, Beijing, Beijing Municipality 100142 China
Chongqing Cancer Hospital, Chongqing, Chongqing Municipality 400030 China
Fujian Medical University Union Hospital, Fuzhou, Fujian 350001 China
Guangdong Academy of Medical Sciences Guangdong Provincial People's Hospital, Guangzhou, Guangdong 519041 China
Sun Yat-sen University Cancer Center, Guangdong, Guangzhou 510062 China
Affiliated Hospital of Nantong University, Nantong, Jiangsu 226006 China
Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225009 China
The First Hospital of China Medical University, Shenyang, Liaoning 110002 China
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning 110801 China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18-70 years old; 2. ECOG score 0 or 1; 3. ER+/HER2- confirmed by histopathology after early breast cancer surgery(ER positive is defined as immunohistochemistry(IHC) detection of ER ≥ 1% HER2-negative is defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (Fluorescence in situ hybridization (FISH), Chromogenic in situ hybridization (CISH) , or Silver in situ hybridization (SISH)) test is required by local laboratory testing.); definition of SNF3 subtype: SNF3 subtype confirmed by digital pathology of H\&E sections; 4. Postoperative pathological stage T2-4N0-3M0; 5. Patients who have previously received neoadjuvant chemotherapy and/or adjuvant chemotherapy; 6. Time of randomization from surgery does not exceed 16 months; 7. Time of endocrine therapy from last non-endocrine anti-tumor treatment does not exceed 12 weeks; 8. Has adequate organ function meeting the following criteria: (1) adequate bone marrow function: hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); absolute neutrophil count ≥ 1.5 x 10\^9 /L; platelet count ≥ 100 \* 10\^9 /L; (2)adequate liver and kidney function: Alanine Aminotransferase (ALT) ≤ 3×upper limit of normal (ULN), Aspartate Aminotransferase (AST) ≤ 3×ULN, Total Bilirubin (TBIL)≤ 1.5×ULN, serum creatinine ≤ 1×ULN,and with endogenous creatinine clearance rate of \>50 ml/min (Cockcroft-Gault formula); 9. Patients receiving radiotherapy must recover from the acute phase reaction of radiotherapy, with a washout period of at least 14 days from the end of radiotherapy to randomization; 10. Patients who received chemotherapy in the early stage must recover from acute adverse reactions to chemotherapy (\[CTCAE\] grade ≤ 1) before randomization, except for hair loss or grade 2 peripheral neuropathy. There is a washout period of at least 21 days from the last chemotherapy administration to randomization (assuming the patient has not received radiotherapy); 11. Patients can take medication orally on their own; 12. Female subjects with fertility are required to use a medically approved contraceptive method during the study treatment 13. Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up. Exclusion Criteria: 1. Has bilateral breast cancer; 2. Has previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ. 3. Has metastatic (Stage 4) breast cancer; 4. Is pregnant, is breast feeding women, or women of childbearing age who cannot practice effective contraceptives; 5. Patients participating in other clinical trials at the same time; 6. Has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (LVEF) \< 50% (cardiac ultrasound); severe cardio cerebral vascular disease within the 6 months previous of randomization (such as unstable angina, chronic heart failure, uncontrolled hypertension with blood pressure\>150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension; 7. Has known allergy to fluzoparib and excipients. 8. Has severe or uncontrolled infection; 9. Has a history of psychotropic substance abuse and were unable to abandon drug habits, or those with history of mental disorders; 10. The researchers judged patients to be unsuitable for the study.
Conditions Triple-Negative Breast Cancer
Phase PHASE3
Enrollment 223
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The study is being conducted to evaluate the Famitinib with Camrelizumab plus treatment of physician's choice (TPC) versus Camrelizumab plus TPC in Patients with Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Famitinib — TKI
  • Drug: Camrelizumab — PD1 inhibitor
  • Drug: nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin — TPC

Primary Outcomes

  • PFS (Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 1.5 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-03-17
Completion: 2027-01-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 223 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Zhimin Shao
86-021-64175590
zhimingshao@yahoo.com
Zhi-Ming Shao, MD
86-21-641755901105
zhimingshao@yahoo.com
Breast cancer institute of Fudan University Cancer Hospital
Lei Fan, MD
86-21-641755901105
cmchen@medmail.com.cn
Breast cancer institute of Fudan University Cancer Hospital
Interventions
  • Drug: Famitinib — TKI
  • Drug: Camrelizumab — PD1 inhibitor
  • Drug: nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin — TPC
Study Locations (1 sites)
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: * ECOG Performance Status of 0-1 * Expected lifetime of not less than three months * Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression) * Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resection. * Adequate hematologic and end-organ function, laboratory test results. * Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) • Patients had received no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer Exclusion Criteria: * Previous received anti-VEGFR small molecule tyrosine kinase inhibitors (e.g. famitinib, sorafenib, Sunitinib, regorafenib, etc.) for treatment of the patients . * A history of bleeding, any serious bleeding events. * Important blood vessels around tumors has been infringed and high risk of bleeding. * Coagulant function abnormality * artery/venous thromboembolism event * History of autoimmune disease * Positive test for human immunodeficiency virus * Active hepatitis B or hepatitis C * Uncontrolled pleural effusion and ascites • Known central nervous system (CNS) disease. * Long-term unhealing wound or incomplete healing of fracture * urine protein ≥2+ and 24h urine protein quantitative \> 1 g. * Pregnancy or lactation. * Thyroid dysfunction. * Peripheral neuropathy grade ≥2. * People with high blood pressure; * A history of unstable angina; * New diagnosis of angina pectoris. * Myocardial infarction incident .
Conditions HER2-negative Breast Cancer, Leptomening...
Phase PHASE4
Enrollment 37
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, multicenter, randomized controlled, open-label investigator-initiated clinical study to evaluate the clinical efficacy and quality of life of intrathecal chemotherapy through Ommaya reservoir in combination with systematic chemotherapy versus systemic chemotherapy alone in patients with Her-2 negative breast cancer with leptomeningeal metastasis.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Ommaya reservoir — Intrathecal chemotherapy through Ommaya reservoir
  • Drug: Systematic chemotherapy — Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(60mg/m2, qw, po), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), iribrin(1.4mg/m2, d1,8, q3w, ivgtt), DS8201(5.4mg/kg, d1, q3w, ivgtt), sacituzumab govitecan(10mg/kg, d1,8, q3w, ivgtt) or SKB264(5mg/kg, d1, q2w, ivgtt).
  • Drug: Intrathecal chemotherapy — Intrathecal chemotherapy through Ommaya reservoir: including MTX(10-12mg, q1-3w), thiotepa(10mg, q1-3w), cytarabine(30mg/m2, q1-3w), cytarabine liposome(50mg, q1-3w), pemetrexed(50mg, q1-3w), or DS8201(The frequency and cycle of drug administration are determined based on the results of the Phase I/II clinical trial of intrathecal injection of DS8201 in our center).

Primary Outcomes

  • Neural progression-free survival (NPFS) (Six months after the last patient was enrolled)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-01-05
Completion: 2027-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 37 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Jian Zhang
+8664175590
syner2000@163.com
Yuxin Mu
34778299
Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University
Interventions
  • Device: Ommaya reservoir — Intrathecal chemotherapy through Ommaya reservoir
  • Drug: Systematic chemotherapy — Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(60mg/m2, qw, po), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), iribrin(1.4mg/m2, d1,8, q3w, ivgtt), DS8201(5.4mg/kg, d1, q3w, ivgtt), sacituzumab govitecan(10mg/kg, d1,8, q3w, ivgtt) or SKB264(5mg/kg, d1, q2w, ivgtt).
  • Drug: Intrathecal chemotherapy — Intrathecal chemotherapy through Ommaya reservoir: including MTX(10-12mg, q1-3w), thiotepa(10mg, q1-3w), cytarabine(30mg/m2, q1-3w), cytarabine liposome(50mg, q1-3w), pemetrexed(50mg, q1-3w), or DS8201(The frequency and cycle of drug administration are determined based on the results of the Phase I/II clinical trial of intrathecal injection of DS8201 in our center).
Study Locations (1 sites)
Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Male or female aged 18 years or above; 2. Can understand the purpose of clinical trials and the benefits and risks, voluntarily participate in and sign the informed consent 3. The physical status score of the Eastern Oncology Consortium (ECOG) was ≤3; 4. HER2-metastatic breast cancer confirmed histologically or cytologically (HER2- is defined as either a standard immunohistochemical (IHC) test result of 0 or 1+, or an IHC test result of 2+ and a negative ISH test result); 5. Failure of standard treatment, or intolerance to standard treatment; 6. pial metastasis is present, which is defined as meningeal metastasis confirmed by malignant tumor cells found in cerebrospinal fluid cytology; Or clinical symptoms/signs suggest meningeal metastasis, and brain MRI suggests pia enhancement; 7. The function of major organs was good, which was confirmed by the following laboratory tests during the screening period: Platelet count ≥80\*10\^9/L Hemoglobin ≥8g/L Neutrophil count ≥1.5\*10\^9/L Serum creatinine ≤1.5\*ULN ALT and AST≤ 3\*ULN (if liver metastases are present, ALT and AST≤5\*ULN) Serum total bilirubin ≤1.5\*ULN International Standardized ratio (INR) and Activated partial thromboplastin time (APTT) ≤1.5\*ULN 8. NYHA cardiac function grade ≤II, no obvious abnormality in ECG, or no clinical significance according to the investigators; 9. Voluntary compliance with the trial protocol during the study period and regular follow-up; 10. For all women of childbearing age, fertile men or their spouses who did not plan to have children or donate sperm during the entire trial period until 6 months after the last dose, or who voluntarily took effective contraception, the blood/urine pregnancy test results of female patients of childbearing age within 7 days before enrollment were negative. 11. Subjects who have recovered from non-hematological toxicity from the last treatment (CTCAE≤ class 1, except for special conditions such as "alopecia") before first administration, and who the investigator determines that the corresponding AE does not pose a safety risk. Exclusion Criteria: 1. Pregnant or lactating women; 2. Patients with acute and chronic infections, or with other serious diseases at the same time, were judged not suitable for this study; 3. Other malignant tumors within 5 years (except the following cases: cured skin basal cell carcinoma, cervical carcinoma in situ, thyroid papillary carcinoma; A second primary cancer that has been eradicated and has not recurred within five years; Both primary cancers are expected to benefit from this study. Investigators have identified the primary tumor source of the metastases); 4. Mental illness or mental disorder, poor compliance can not cooperate with and describe treatment response; 5. There are serious organic diseases or major organ failure, such as decompensated heart and lung failure, which can not tolerate treatment; 6. Patients with bleeding tendency; 7. Patients who have received organ transplants; 8. Patients taking adrenal corticosteroids or immunosuppressants for a long time; 9. Intracranial hemorrhage unrelated to tumor disease; 10. Patients with central nervous system complications requiring urgent treatment; 11. Test group: subjects who could not collect CSF; 12. The subject has a history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases; 13. Active viral hepatitis B (HBsAg positive with HBV DNA≥500 IU/mL) or hepatitis C. Among hepatitis C antibody positive subjects, only those whose polymerase chain reaction showed negative HCV RNA were eligible for enrollment (chronic hepatitis B or chronic hepatitis C patients with stable disease receiving standard antiviral therapy were eligible for enrollment); 14. The subject has a serious cardiovascular clinical disease or symptom, including: Congestive heart failure History of unstable angina; myocardial infarction within the past six months; Clinically significant malignant arrhythmias (except atrial fibrillation and paroxysmal supraventricular tachycardia); Subjects had clinically significant prolonged QTcF High blood pressure that is not well controlled; 15. The researcher believes that the patient has other conditions that are not suitable for participating in this study.
Conditions Breast Cancer, Triple Negative Breast Ca...
Phase PHASE2
Enrollment 40
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacituzumab govitecan * Atezolizumab

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Atezolizumab — Atezolizumab is a type of antibody and is administered intravenously.
  • Drug: Sacituzumab govitecan — Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously

Primary Outcomes

  • Rate of undetectable circulating tumor cfDNA- 6 Cycles (18 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2020-07-02
Completion: 2027-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dana-Farber Cancer Institute
Collaborators: Genentech, Inc., Stand Up To Cancer
Principal Investigators:
  • Elizabeth A Mittendorf, MD, PhD (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
Contact Information
Study Contact:
Elizabeth A Mittendorf, MD, PhD
617-713-2294
emittendorf@bwh.harvard.edu
Jo Chien, MD
jchien@medicine.ucsf.edu
University of California San Francisco
Jo Chien, MD
University of California San Francisco
Interventions
  • Drug: Atezolizumab — Atezolizumab is a type of antibody and is administered intravenously.
  • Drug: Sacituzumab govitecan — Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously
Study Locations (7 sites)
University of California San Francisco, San Francisco, California 94115 United States
University of Chicago Medical Center, Chicago, Illinois 60637 United States
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois 60451 United States
University of Chicago Medical Center for Advanced Care Orland Park, Orland Park, Illinois 60462 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
University of Pennsylvania-Abramson Cancer Center, Philadelphia, Pennsylvania 19104 United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: * Pathologically confirmed residual invasive breast cancer, in the breast and/or lymph node(s), following neoadjuvant chemotherapy. In the absence of residual invasive disease in the breast, lymph node must contain at least 2mm of invasive disease. * HER2 negative in primary tumor pre-treatment by local pathology assessed according to current ASCO/CAP guidelines: * In situ hybridization non-amplified (ratio of HER2 to CEP17 \< 2.0 or single probe average HER2 gene copy number \< 4 signals/cell), OR * Immunohistochemistry (IHC) 0 or IHC 1+. * NOTE: If more than one test result is available and not all results meet the inclusion criterion definition, all results should be discussed with the Principal Investigator to establish eligibility * ER and PR negative in primary tumor pre-treatment defined as \< 10% of cells expressing hormonal receptors via IHC analysis by local laboratory assessment. * Patients must have received neoadjuvant chemotherapy prior to breast surgery. * Patients must be within 4 months of completion of all locoregional therapy (either last surgery or last dose of radiation, whichever is later) . Definitive breast surgery must have been performed and includes lumpectomy or mastectomy with pathologically clear margins (i.e. no ink on tumor). For patients undergoing lumpectomy, this must be followed by whole breast irradiation. Definitive surgery also includes axillary surgery, either sentinel lymph node biopsy or axillary lymph node dissection at the discretion of the attending surgeon. * Evidence of ctDNA in blood sample collected after completion of all local and systemic neoadjuvant therapy (preoperative chemotherapy, surgery and radiation), confirmed by central testing. Detection of any tumor specific mutations (TSMs) within the sample will be considered positive for purposes of study eligibility. * Concurrent receipt of bone modifying agents (bisphosphonates or rank-ligand inhibitors)is allowed. * Prior treatment with an immune checkpoint inhibitor in the neoadjuvant setting is permitted. * ECOG Performance Status of 0 or 1 * Men and women, age ≥ 18 years * Adequate hematologic and organ function defined by the following: * ANC ≥ 1.5 × 109/L (1500/μL) without granulocyte colony-stimulating factor support * WBC count ≥ 2.5 × 109/L (2500/μL) * Absolute Lymphocyte count ≥ 0.5 × 109/L (500/μL) * Platelet count ≥ 100 × 109/L (100,000/μL) * Hemoglobin ≥ 90 g/L (9.0 g/dL), with or without transfusion * AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 × institutional upper limit of normal (ULN). * Serum bilirubin ≤ 1.5 × institutional ULN with the following exception: * Patients with known Gilbert syndrome: serum bilirubin level ≤ 3 × institutional ULN * Serum creatinine \< 1.5 x institutional ULN * Creatinine clearance ≥30 mL/min as assessed by the Cockcroft-Gault equation * Serum albumin ≥ 25 g/L (2.5 g/dL) * For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 × institutional ULN * For patients receiving therapeutic anticoagulation: stable anticoagulant regimen * Women of childbearing potential (pre-menopausal) must have a negative serum or urine pregnancy test within 7 days prior to start of therapy. A woman is defined as premenopausal if she is less than 12 months from last menstrual period with no identified cause other than menopause (medication induced amenorrhea is not acceptable). Pregnancy test is not required in women who are surgically sterile via bilateral salpingooophorectomy or hysterectomy. * Women of childbearing potential and men must agree to use adequate contraception for the duration of protocol treatment and for 6 months after last dose of atezolizumab and 6 months after last dose of sacituzumab govitecan, whichever is later. Hormonal contraceptives are not acceptable (see section 5.6). * Ability to understand and the willingness to sign a written informed consent document. Non-English speakers are eligible to participate but will be excluded from surveys/questionnaires unless the participant has a proxy available for translation. Exclusion Criteria: * Prior therapy with sacituzumab govitecan, irinotecan, or any topoisomerase I-containing antibody-drug conjugates at any time for early stage disease. * Receipt of adjuvant chemotherapy (all chemotherapy prior to registration must have occurred in the preoperative setting) * Prior hypersensitivity to atezolizumab or the excipients of atezolizumab or sacituzumab govitecan * Clinical or radiographic evidence of metastatic disease * Residual DCIS or LCIS alone without invasive cancer OR pT0N0i and pT0N1mic residual disease * Concurrent enrollment on another investigational therapy trial * Prior treatment-related toxicity must be resolved to ≤ Grade 1 prior to study enrollment with the exception of alopecia and peripheral neuropathy, prior to study enrollment. * Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study * Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study. * Intercurrent illness including, but not limited to: ongoing or active infection requiring systemic therapy, active tuberculosis, serious liver disease such as cirrhosis, active bleeding diathesis, uncontrolled Type I or Type II diabetes mellitus, Grade ≥ 2 uncontrolled or untreated hypercholesterolemia, Hypertriglyceridemia or hypercalcemia * Cardiovascular disease including: congestive heart failure of New York Heart Association Class III or IV, myocardial infarction (\<6 months prior to enrollment) unstable angina pectoris, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease, in the opinion of the investigator * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted. * Active (acute or chronic) autoimmune disease of any type except hypothyroidism on a thyroid-replacement hormone, celiac disease, or well-controlled psoriasis, eczema, lichen simplex chronicus or vitiligo. * Impairment of gastrointestinal function or active gastrointestinal disease that may significantly alter the absorption of the study agents (e.g., ulcerative disease, uncontrolled nausea(\> grade 2), vomiting (\> grade 2), diarrhea (\> grade 2), malabsorption syndrome or small bowel resection). * Congenital long QT syndrome or screening QT interval corrected through use of Fridericia's formula \>480 ms. * Participants known to be positive for the human immunodeficiency virus (HIV), Hepatitis B antigen (HepBsAg), or Hepatitis C virus (HCV) RNA are ineligible. * History of prior invasive breast cancer in either breast. * Participants with history of prior malignancy other than breast cancer are eligible if they have been disease-free for at least 5 years prior to enrollment with the exception of patients with thyroid cancer that has been definitively treated without spread to regional lymph nodes. * Treatment with strong strong UGT1A1 inhibitor or inducer within 4 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug. * Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine while on protocol treatment * Known allergy or hypersensitivity to any of the study drugs or any of their excipients, including chimeric or humanized antibodies or fusion proteins and Chinese hamster ovary cell products or recombinant hu